Jiun-Lu Lin, Sung-Chen Liu, Tze-Fan Liu, Shih-Ming Chuang, Chun-Ta Huang, Ying-Ju Chen, Chun-Chuan Lee, Ming-Nan Chien, Charles Jia-Yin Hou, Hung-I Yeh, Chern-En Chiang, Chung-Lieh Hung
BACKGROUND: Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, is an epochal oral antidiabetic drug that improves cardiorenal outcomes. However, the effect of early dapagliflozin intervention on left ventricular (LV) remodeling in patients with type 2 diabetes free from cardiovascular disease remains unclear. METHODS AND RESULTS: The ELUCIDATE trial was a prospective, open-label, randomized, active-controlled study that enrolled 76 patients with asymptomatic type 2 diabetes with LV ejection fraction ≥50%, randomized to the dapagliflozin 10 mg/day add-on or standard-of-care group...
April 19, 2024: Journal of the American Heart Association